Part 1 results from NOVA-II, a randomized, double-blind, vehicle-controlled phase II study evaluating the safety and efficacy of OQL011 on VEGFR inhibitor associated hand-foot skin reaction in cancer patients Meeting Abstract
| Authors: | Lacouture, M. E.; Patel, A. B.; Le Boeuf, N. R.; Marathe, O. S.; Leventhal, J.; Choi, J. N.; Lam, E. T.; Kaffenberger, B. S.; Voss, M. H.; Webb, M. L.; Tyler, R. C.; Ju, J.; Tang, H.; Luo, J.; Anadkat, M. J.; Vogelzang, N. J. |
| Abstract Title: | Part 1 results from NOVA-II, a randomized, double-blind, vehicle-controlled phase II study evaluating the safety and efficacy of OQL011 on VEGFR inhibitor associated hand-foot skin reaction in cancer patients |
| Meeting Title: | 2022 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2022 Feb 17-19 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-02-20 |
| Language: | English |
| ACCESSION: | WOS:000771008900401 |
| DOI: | 10.1200/JCO.2022.40.6_suppl.TPS396 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS396 -- Meeting was conducted online as well as in person -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work